GET DAILY SIGNALSDaxor (DXR) Q3 2026 Earnings: Tracking +16% Kit Sales Growth
Key Takeaways
- Daxor Corporation (DXR) is expected to report its fiscal third-quarter 2026 results around November 13, 2026, covering the period ended September 30, 2026.
- The company develops the BVA-100 blood-volume analyzer, and management reported kit sales up 16% year-over-year in the first half of 2026.
- In the prior quarter (Q2 2026, ended June 30, 2026), Daxor posted a loss of $0.06 per share on revenue of $2.0 million, both below limited analyst expectations.
- Consensus expectations for Q3 2026 remain modest and thinly covered, with revenue estimates generally in the low single-digit millions and EPS still slightly negative.
- Key watch items include commercial momentum for the newly FDA-cleared next-generation analyzer and early contributions from the Isotex Diagnostics acquisition.
- For more detail on DXR's Major News, Today's Price Move, Price Targets, and Forecasts, explore Tickeron's dedicated pages.
- You can also explore Trending AI Robots to see AI-driven trading strategies currently active in the market.
Why This Earnings Report Matters
Daxor Corporation is a medical instrumentation and biotechnology company best known for its BVA-100 system, a diagnostic platform that measures blood volume to guide fluid-management decisions in conditions such as heart failure and critical illness. The company has been shifting from its historical closed-end investment-company structure toward a pure-play medical diagnostics and technology operation, a transition that makes each quarterly report an important progress check. Investors are watching whether rising kit sales can translate into sustained commercial growth, especially as the company rolls out its next-generation analyzer following FDA clearance. With a small market capitalization, thin trading volume, and limited analyst coverage, DXR shares can react sharply to operational updates, making the earnings preview a focal point for both existing shareholders and potential new investors. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What to Expect from Q3 Results
Analyst coverage of Daxor remains limited, so consensus figures are thinner than those for larger medical-device peers. Available estimates point to Q3 2026 revenue in the $2.5 million to $3.2 million range, with EPS expected to remain modestly negative. For context, Daxor reported Q1 2026 revenue of $1.9 million and a loss of $0.11 per share, followed by Q2 2026 revenue of $2.0 million and a loss of $0.06 per share — the latter missing limited forecasts that had projected roughly $2.8 million in revenue and a $0.03 per-share loss.
Given the company's low revenue base, investors will focus less on headline EPS and more on operational indicators, including kit sales growth, new hospital and practice placements, and progress toward the company's stated goal of accelerating kit sales in the second half of 2026. Management has pointed to an expanded commercial team and more than fifteen indications of interest from hospitals and practices as early signs of demand for the next-generation BVA systems.
Market Sentiment Ahead of the Report
Sentiment heading into the Q3 2026 report is cautious. DXR is a low-volume, small-cap stock, and its most recent quarterly release underscored the gap between commercial progress and near-term profitability. The shares have traded within a relatively wide band over the past year, and investors appear focused on whether the company can convert its FDA clearance and the Isotex Diagnostics acquisition into measurable revenue growth. Because the company has no outstanding debt and reported net assets of $51.83 million as of June 30, 2026, balance-sheet risk is limited, but execution risk on the commercial rollout remains the central theme. Any commentary on new placements, kit reorder rates, or manufacturing capacity will likely drive the immediate post-earnings reaction.
Looking Ahead: What to Watch
Looking beyond the Q3 2026 print, investors should monitor several forward-looking themes. First is the pace of commercial expansion. Management has signaled an expectation of accelerated kit sales growth in the second half of 2026 and into 2027 as the enlarged sales team ramps up, so actual quarterly kit sales and new system placements will be a direct test of that guidance.
Second is the rollout of the next-generation BVA analyzer following its FDA clearance. The ability to convert early indications of interest from hospitals and practices into committed contracts and recurring kit revenue will be a key driver of the company's longer-term trajectory. Any updates on manufacturing capacity and inventory investment will also matter, since supply constraints could temper near-term growth.
Finally, investors should watch the integration of the Isotex Diagnostics acquisition and any updates on intellectual property or new patents, which could expand the company's addressable market. Given Daxor's small size and thin coverage, these operational disclosures — rather than headline EPS — are likely to shape both the stock's reaction and its fundamental narrative in the quarters ahead.
Integrating AI Tools in My Research
In my day-to-day analysis, I often rely on Tickeron’s AI Screener to quickly filter small-cap names like DXR by fundamentals, technical patterns, and sector trends. It helps surface relevant comparables and spot potential opportunities without spending hours on manual screens, which keeps my workflow efficient when preparing for reports like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DXR in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 22, 2026
DXR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 38 cases where DXR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DXR's RSI Indicator exited the oversold zone, 15 of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
Following a +3.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXR advanced for three days, in 141 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Bearish Trend Analysis
DXR moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DXR crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for DXR entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.952) is normal, around the industry mean (4.964). P/E Ratio (5.000) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (3.480) is also within normal values, averaging (4.143). Dividend Yield (0.014) settles around the average of (0.005) among similar stocks. P/S Ratio (8.389) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. DXR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of original medical equipment for medical personnel
Industry PharmaceuticalsOther
Advertisement